Drug intelligence / Profile preview

KD2406

Development stage: Preclinical
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules
Administration: Intranasal, Subcutaneous

Overview

KD2406 is a small molecule improved new drug (개량신약) being developed by Kyungdong Pharmaceutical for the treatment of gastrointestinal diseases. Currently in the discovery stage, the drug is part of Kyungdong's pipeline of improved new drugs, which typically involve modifications to existing drugs such as new formulations, salts, or combinations to enhance efficacy or safety. Specific details regarding its molecular target or the exact gastrointestinal indication have not yet been released.

Beyond the preview

Go deeper on KD2406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD2406.

Explore the full profile